CNTN2 and myeloid sarcoma: The presence of CNTN2 autoantibodies in the serum of MS patients could not differentiate between early occurrence and stages of MS (clinically isolated syndromes, relapsing–remitting, secondary-progressive, and primary-progressive) or different MRI profiles [102].